Galera Therapeutics, Inc.
GRTX
$0.0235
-$0.0004-1.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.70% | -31.14% | -69.94% | -53.26% | -60.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -68.64% | -66.23% | -74.96% | -67.03% | -60.74% |
| Operating Income | 68.64% | 66.23% | 74.96% | 67.03% | 60.74% |
| Income Before Tax | 11.74% | 61.63% | 80.38% | 75.26% | 65.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.74% | 62.97% | 80.38% | 75.26% | 65.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.74% | 62.97% | 80.38% | 75.26% | 65.49% |
| EBIT | 68.64% | 66.23% | 74.96% | 67.03% | 60.74% |
| EBITDA | 67.28% | 66.24% | 74.97% | 67.04% | 62.30% |
| EPS Basic | 13.24% | 69.04% | 84.52% | 84.00% | 82.27% |
| Normalized Basic EPS | 80.84% | 76.28% | 84.52% | 84.01% | 82.35% |
| EPS Diluted | 13.24% | 69.04% | 84.52% | 84.00% | 82.27% |
| Normalized Diluted EPS | 80.84% | 76.28% | 84.52% | 84.01% | 82.35% |
| Average Basic Shares Outstanding | 1.79% | 19.60% | 26.74% | 54.54% | 94.63% |
| Average Diluted Shares Outstanding | 1.79% | 19.60% | 26.74% | 54.54% | 94.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |